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Abstract
Background Cancer cachexia occurs in approximately 80% of cancer patients and is a key contributor to cancer-related
death. The mechanisms controlling development of tumour-induced muscle wasting are not fully elucidated. Specifically,
the progression and development of cancer cachexia are underexplored. Therefore, we examined skeletal muscle protein
turnover throughout the development of cancer cachexia in tumour-bearing mice.
Methods Lewis lung carcinoma (LLC) was injected into the hind flank of C57BL6/J mice at 8 weeks age with tumour allowed
to develop for 1, 2, 3, or 4 weeks and compared with PBS injected control. Muscle size was measured by cross-sectional area
analysis of haematoxylin and eosin stained tibialis anterior muscle. 2H2O was used to assess protein synthesis throughout the
development of cancer cachexia. Immunoblot and RT-qPCR were used to measure regulators of protein turnover. TUNEL
staining was utilized to measure apoptotic nuclei. LLC conditioned media (LCM) treatment of C2C12 myotubes was used to
analyse cancer cachexia in vitro.
Results Muscle cross-sectional area decreased ~40% 4 weeks following tumour implantation. Myogenic signalling was
suppressed in tumour-bearing mice as soon as 1 week following tumour implantation, including lower mRNA contents of
Pax7, MyoD, CyclinD1, and Myogenin, when compared with control animals. AchRδ and AchRε mRNA contents were down-
regulated by ~50% 3 weeks following tumour implantation. Mixed fractional synthesis rate protein synthesis was ~40% lower
in 4 week tumour-bearing mice when compared with PBS controls. Protein ubiquitination was elevated by ~50% 4 weeks after
tumour implantation. Moreover, there was an increase in autophagy machinery after 4 weeks of tumour growth. Finally, ERK
and p38 MAPK phosphorylations were fourfold and threefold greater than control muscle 4 weeks following tumour implanta-
tion, respectively. Inhibition of p38 MAPK, but not ERK MAPK, in vitro partially rescued LCM-induced loss of myotube diameter.
Conclusions Our findings work towards understanding the pathophysiological signalling in skeletal muscle in the initial
development of cancer cachexia. Shortly following the onset of the tumour-bearing state alterations in myogenic regulatory
factors are apparent, suggesting early onset alterations in the capacity for myogenic induction. Cancer cachexia presents with
a combination of a loss of protein synthesis and increased markers of protein breakdown, specifically in the ubiquitin-
proteasome system. Also, p38 MAPK may be a potential therapeutic target to combat cancer cachexia via a p38-FOX01-
atrogene-ubiquitin-proteasome mechanism.
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Introduction
Cancer is one of the leading causes of death worldwide with
over half of the people affected by cancer dying as a result of
the condition.1,2 Cancer cachexia is a wasting syndrome that
occurs in approximately 80% of cancer patients.3–5 In fact,
cancer cachexia is the primary cause of death for 20–40%
of cancer deaths.3–5 Cancer cachexia is defined as a multifac-
torial syndrome that displays an ongoing loss of skeletal mus-
cle mass (with or without loss of fat mass) that cannot be
fully reversed by conventional nutritional support and leads
to progressive functional impairment.3,5 As efforts to reverse
cancer cachexia have been largely unsuccessful, recent sug-
gestions in the literature have emphasized needs to focus
on prevention of the condition.6 However, few efforts have
been placed towards understanding the early stage develop-
ment of cancer cachexia. We recently demonstrated that
multiple measures of muscle mitochondrial health are im-
paired well before onset of measurable muscle wasting in
cancer cachexia in Lewis lung carcinoma (LLC) tumour-
bearing mice beginning with increased mitochondrial ROS
emission, followed by network degeneration and eventual
decrements in respiratory function using this same time
course model.7 Those data suggest early onset derangements
in muscle health. However, skeletal muscle atrophy occurs
primarily by an imbalance of protein turnover favouring
protein degradation over protein synthesis.8,9 Therefore, a
critical need remains to define alteration of muscle protein
turnover processes in the initial development of cancer
cachexia induced muscle wasting.
From prior literature, it is clear that cancer cachexia is as-
sociated with decreased rates of muscle protein synthesis
and increased rates of protein degradation.10–13 We also
know that protein turnover is regulated by a series of
anabolic processes including myogenesis and protein synthe-
sis10–22 and catabolic processes including the ubiquitin-
proteasome system, autophagy, and apoptosis.8,13,23–28 Each
of these processes may present significant dysregulation
during cancer cachexia; however, the nature by which this
negative protein balance initially develops in cancer cachexia
remains largely unknown. The initial development of cancer-
induced muscle wasting is understudied in scientific literature
despite the need to consider measures to prevent the condi-
tion. To this point, other prior studies have examined pro-
gression of cancer cachexia;15,29 although in most cases,
focus is placed on varying degrees of cachexia rather than
the initial onset of muscle loss. In fact, a prior study by White
et al.15 previously demonstrated a clear and progressive re-
duction in protein synthesis and induction of protein
ubiquitination with worsening of cachexia. However, in their
work, efforts were focused on progression through worsen-
ing cachexia and did not examine protein turnover and other
anabolic/catabolic processes in the pre-wasting state as com-
pared with healthy control. Therefore, the purpose of this
study was to examine regulation of protein turnover in
skeletal muscle throughout a time course progression of
cancer cachexia in tumour-bearing mice. By examining a com-
prehensive measurement of protein turnover regulation
throughout the progression of cancer cachexia, we provide
key information about the pathogenesis of this condition. In
doing so, we identified that the onset of negative protein bal-
ance and muscle wasting is met with the induction of MAPK
systems. Therefore, to determine the potential of targeting
MAPKs in preventive efforts to cachectic wasting, we used
LLC conditioned media (LCM) to mimic cancer cachexia
in vitro, combined with inhibitors specific to p38 and MEK
(upstream of ERK MAPK).30,31 The data presented herein
present novel insight to the onset of the negative protein
balance in cancer cachexia and provide evidence for




Animal experiments were performed at the University of
Arkansas, Fayetteville. All procedures were approved by the
Institutional Animal Care and Use Committee of the
University of Arkansas. We have previously reported on
several aspects regarding body and tissue masses and mito-
chondrial health in these same animals.7
Tumour implantation and tissue collection
Male C57BL/6J mice were purchased from Jackson Laborato-
ries (Bar Harbor, ME USA). The mice were kept on a 12:12 h
light–dark cycle with ad libitum access to normal rodent chow
and water; 1×106 LLC cells suspended in sterile PBS were im-
planted subcutaneously to the hind flank of mice at 8 weeks
of age.7 The tumour was allowed to develop for 1, 2, 3 or
4 weeks as previously described.7 For control, a cohort of ani-
mals was given an injection of equal volume sterile PBS at
8 weeks of age and then age-matched to 4 week tumour-
bearing mice at time of harvest (12 weeks of age). Animals
were not fasted at time of tissue collection. To allow measure
of protein synthesis, a bolus of deuterium oxide (~20 μL/g
body weight) was injected intraperitoneally in the mouse ap-
proximately 24 h before tissue collection. Drinking water was
thereafter supplemented with deuterium oxide (4% deute-
rium oxide drinking water) in order to maintain the plasma
pool of deuterium oxide.32–34 Animal tissues were quickly
collected under isoflurane anaesthesia prior to euthanasia.
Tissues were quickly weighed, enrichment time noted, and
snap-frozen in liquid nitrogen for further processing and
stored at 80°C.
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Histology
Tibialis anterior (TA) muscles were imbedded in optimal
cutting temperature compound and frozen for sectioning.
Sections were cut at 10 μm using a Leica CM1859 cryostat
(Leica Biosystems, Buffalo Grove, IL, USA) and stained with
haematoxylin and eosin for cross-sectional area analysis.
Muscle fibres were circled using Nikon Basic Research
Imaging Software (Melville, NY, USA). Roche Diagnostics (In-
dianapolis, IN, USA) In Situ Cell Death Detection Fluorescein
(11684795910) was used to detect damaged DNA. Manufac-
turer’s protocols were used. Slides were mounted with fluo-
rescent mounting media with DAPI (ProLong Gold antifade
reagent with DAPI, Invitrogen P36931). Nikon Ti-S inverted
epiflourescent microscope with LED-based light source was
used to image total nuclei (DAPI) and TUNEL + nuclei (FITC).
Total nuclei and TUNEL + nuclei were then counted using
Nikon Basic Research Imaging Software.
24 h protein synthesis in vivo
A detailed description of this method for measuring protein
synthesis has previously been published35; 15 and 35 mg of
gastrocnemius muscle were powdered and homogenized in
a 10% TCA solution for mixed and myofibrillar FSR, respec-
tively. In order to isolate the myofibrillar fraction, homoge-
nate was centrifuged at 600× g for 15 min. The supernatant
containing cytosolic proteins was then discarded. Mixed and
myofibrillar fractions were then washed three times with
10% TCA solution by centrifugation to eliminate cytosolic
amino acids. Proteins were placed in 6 M HCL at 100°C hydro-
lyze proteins into amino acids. An aliquot of the hydrolysate
was dried down and derivatized with a 3:2:1 v/v solution of
methyl-8, methanol, and acetonitrile to determine 2H-
labelling of alanine on its methyl-8 derivative. The solution
was then placed in a GC–MS capillary column (Agilent
7890A GC HP-5 ms capillary column) and positioned in the
GC–MS; 1 μL of solution was ran on the Agilent GC–MS at
an 80:1 split. GC–MS settings have previously been de-
scribed.33,35 A ratio of deuterated alanine over alanine was
employed to assess protein synthesis.
The precursory pool of 2H2O in the plasma was reacted
with 10 M NaOH and a 5% solution of acetone in acetonitrile
for 24 h in order to conjugate the free 2H2O to acetone. The
solution was extracted by adding Na2SO4 and chloroform and
placed in capillary columns to be analysed on the GC–MS to
detect acetone at an 80:1 split.
FSR of mixed and myofibrillar proteins were calculated
using the equation EA × [EBW × 3.7 × t (h)]  1 × 100, where
EA represents amount of protein-bound [2H] alanine (mole%
excess), EBW is the quantity of 2H2O in body water (mole%
excess), 3.7 represents the exchange of 2H between body wa-
ter and alanine (3.7 of 4 carbon-bound hydrogens of alanine
exchange with water) and t (h) represents the time the label
was present in hours.
RNA isolation, cDNA synthesis, and quantitative
real-time PCR
Adult gastrocnemius muscles were collected and frozen in liq-
uid nitrogen at time of harvest; 20–30 μg of powdered gas-
trocnemius muscle was homogenized into a 1 mL TRIZOL
solution, and RNA was isolated using a commercially available
kit (Ambion and Life Technologies). Isolated RNA purity and
concentration was confirmed using Bio-Tek (Winooski, VT,
USA) Power Wave XS plate reader with Take3 microvolume
plate and Gen5 software. After which, 1 μg of RNA was re-
verse transcribed into cDNA using previously described
methods and Vilo SuperScript (11755050, Invitrogen,
Carlsbad, CA, USA) reagents cDNA was diluted to 1:100
(10 ng/μL) and Ct values analysed using TaqMan reagents
and commercial Step-One real-time RT-PCR instrumentation
(Applied BioSystems, Foster City, CA, USA). Assessment of
18 s (Mm03928990_g1), Pax7 (Mm01354484_m1), MyoD
(Mm00440387_m1), MyoG (Mm00446194_m1) Atrogin1
(Mm00499523_m1), MuRF1 (Mm01185221_m1), and Cyclin
D1 (Mm00432359_m1) were performed using TaqMan
probes (Life Technologies) and corresponding TaqMan re-
agents. No differences were seen in 18 s among experimental
conditions for experiments presented. Final quantification of
gene expression was calculated using the ΔΔCT method.
Relative quantification was calculated as 2ΔΔCT.
Immunoblotting
Gastrocnemius muscle was homogenized in a buffer contain-
ing 0.23 M Tris–HCL, pH 6.8, 4.5% w/v SDS, 45% glycerol,
0.04% w/v Bromophenol Blue, 80 mM dithiothreitol,
0.57 mM 2-mercaptoethanol, complete, mini protease inhib-
itor cocktail (Roche, Indianapolis, IN, USA), and phosphatase
inhibitor cocktails (Sigma-Aldrich, St. Louis, MO USA) and de-
natured at 95°C. Concentrations were determined using the
RC/DC assay (500–0119, BioRad, Hercules, CA, USA), and
40 μg total protein was resolved by SDS-PAGE, transferred
to a PVDF membrane, and blocked in 3% w/v bovine serum
albumin in Tris-buffered saline with 0.2% Tween 20 (TBST).
Membranes were probed overnight for primary antibodies
specific to p-AKT (Cell Signaling 9271, S 473), AKT (Cell Signal-
ing 9272), Deptor (EMD Millipore, ABS222), p-4EBP1 (Cell Sig-
naling 9451 S 65), 4EBP1 (Cell Signaling 9452), p-p70s6k (Cell
Signaling 9205, T 389), p70s6k (Cell Signaling 9202), p-FOXO1
(Cell Signaling 9464, T24), FOXO1 (Cell Signaling 2880), p-
FOXO3 (Cell Signaling 9464, T32), FOXO3 (Cell Signaling
2497), p-FOXO4 (Cell Signaling 9471, S 197), FOXO4 (Cell Sig-
naling 9472), Ubiquitin (Cell Signaling 3933), Beclin1 (Cell
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Signaling 3738), p62 (Sigma p0067), LC3 (Cell Signaling 4108),
Caspase 3 (Cell Signaling 9662), ERK 1/2 MAPK (Cell Signaling
4695), p-ERK 1/2 MAPK (Cell Signaling 4370, T 202/Y204), p-
p38 MAPK (Cell Signaling 9211, T 180/182), p38 MAPK (Cell
Signaling 9212), p-MAPK APK (Cell Signaling 3316S, T 222),
and MAPK APK (Cell Signaling (3042S) isolated from rabbit
and mouse. Antibodies were diluted in TBST with 5% milk.
LiCor secondary antibodies conjugated with HRP (animal ex-
periments) or Infared (IR) Dye (cell culture experiments) were
used according to manufacturer’s protocols. For animal ex-
periments, membranes were imaged on Protein Simple
FluorChem (Minneapolis, MN, USA) with LiCor WesternSure
Premium Chemiluminescent substrate (926-95000) and
analysed using Alpha View software. For cell culture experi-
ments, membranes were imaged on LiCor Odyssey FC using
IR detection. All bands were normalized to the 45 kDa actin
band of Ponceau S stain as a loading control.
Cell culture experiments
C2C12 myoblasts were plated at 50 000 cells per well of a
six-well cell culture plate with 2 mL DMEM (11965092, Life
Technologies, Carlsbad, CA, USA) supplemented with 20% fe-
tal bovine serum (26140079, Life Technologies) and 1%
pen/strep (15140122, Life Technologies) as per previous work
by us36,37 and others.38 Cell proliferation and differentiation
were performed as previously described,36,37 briefly, at con-
fluence media were switched to DMEM supplemented with
2% horse serum, 1% P/S, 50% HEPES, 0.75% transferrin, and
0.75% insulin for 5 days. Myoblasts were plated for experi-
ments at passage 6.
Lewis lung carcinoma conditioned media
treatment
In order to collect LLC conditioned media (LCM), LLC cells
were grown to 100% confluence as previously described.7,39
LLC cells were then incubated in DMEM supplemented with
10% fetal bovine serum and 1% pen/strep for 18 h. The me-
dia were then collected and filtered. LLC conditioned media
were then diluted to 25% total volume in serum free media.
For the control group, 25% total volume of 10% fetal bovine
serum growth media was diluted in serum free media. C2C12
myotubes were then treated with either control or LCM for
24 h. This method was adapted from Puppa et al.16 and
Guohua et al.31 Dilution of conditioned media should reduce
effects of nutrient deprivation following the incubation
period. Notably, recent works show that both conditioned
media and co-culture with tumour cells (C26) induce
myotube atrophy,40 and thus, effects described herein are
believed to be due to tumour-derived factors rather than
nutrient deprivation.
Inhibition of p38 and ERK 1/2 MAPKs
To examine the roles of p38 MAPK and ERK 1/2 MAPK in the
loss of myotube diameter on the myotubes treated with con-
trol or LCM, differentiated C2C12 myotubes were treated
with PD098059 (20 μM; PHZ1164, Life Technologies)
(MEK1/2 inhibitor preventing ERK 1/2 activity) or SB202190
(20 μM; S7067, Sigma Aldrich) (inhibitor of p38 MAP kinase)
for the entire duration of control or LCM treatment. These
concentrations of inhibitors have been previously published
by Brown et al.36
C2C12 myotube protein and RNA collection
After LCM and drug treatment experiments, myotubes were
collected for immunoblot and RNA isolation by applying
100 μL of 2× protein sample buffer or 1 mL of TRIZOL, respec-
tively. Subsequent steps were performed as described earlier.
Myotube diameter analysis
Myotube diameter analysis was performed as previously
published.36,37 Briefly, C2C12 myoblasts proliferated until
80–100% confluency. The myoblasts were differentiated for
120 h. Myotubes were then placed in control or LCM, and ap-
propriate drug treatments were added. Myotubes were im-
aged with a 40× objective with 10 images per well and 3–4
myotubes examined per well. Five lines were drawn across
the diameter of each myotube in order to measure the aver-
age diameter of the myotube. This was performed on every
myotube imaged in the experimental conditions. Researcher
was blinded for this analysis. A second researcher then re-
peated experiments with images acquired using a 10× objec-
tive and measurements as described earlier. All cell culture
experiments were conducted in triplicate and repeated in
order to ensure data accuracy.
SuNSET protein synthesis
Protein synthesis in tissue culture was measured using the
SuNSET protocol41,42 as we have previously published.37
Briefly, 1 μM puromycin dihydrochloride (Calbiochem, Darm-
stadt, Germany) was added to cell culture media and incu-
bated 30 min prior to protein extraction. Immunoblotting
protocols were followed as described earlier using 1:20 000
dilution of mouse anti-puromycin IgG 2a antibody (EMD
Millipore, Darmstadt, Germany) followed by 1:20 000 dilution
of HRP conjugated anti-mouse IgG fragment specific 2a anti-
body (Jackson ImmunoResearch Labs, West Grove, PA, USA).
The entire lane was assessed for optical density, and this
was normalized to optical density of the entire lane of
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Ponceau S stain. This was used as a relative measure of the
amount of actively translated proteins in the polysome prior
to harvest of cells.
Statistical analysis
For animal experiments, independent factors were PBS and
number of weeks tumour progressed. A one-way ANOVA
was employed as the global analysis for each dependent
variable. For cell culture experiments, independent factors
included media (con or LCM) and drug treatment (vehicle
or SB202190/PD98059 as appropriate to experiment). These
independent factors were divided into two separate cell cul-
ture experiments herein referred to as LCM p38 inhibitor
and LCM ERK 1/2 inhibitor. Data in each separate cell culture
experiment were analysed by two-way ANOVA with factors of
media (Con vs. LCM) and pharmacological inhibition (Vehicle
vs. SB202190 or PD98059). Where significant F-ratios were
found, differences among means were determined by
Student Newman–Keuls post hoc test for both the animal
and cell culture experiments. For all experiments, the
comparison-wise error rate, α, was set at 0.05 for all statisti-
cal tests. All data were analysed using the Statistical Analysis
System (SAS, version 9.3, Cary, NC, USA); figures were
compiled using GraphPad Prism (La Jolla, CA, USA) and data
expressed as mean ± SEM.
Results
Characterization of the progression of Lewis lung
carcinoma-induced cancer cachexia
We have previously reported phenotypic characteristics of
these same mice including body and tissue masses.7 Most im-
portantly, muscle wet weights were ~15–20% lower 4 weeks
following tumour implantation when compared with PBS
control mice.7 Here, we report that mean CSA of TA muscle
fibres was ~15% smaller 3 weeks following tumour implanta-
tion and ~40% smaller by 4 weeks of tumour growth com-
pared with PBS control mice (Figure 1B). Furthermore, there
were a larger number of small fibres (200–600 μM2 area)
and a smaller number of large fibres (>1400 μM2) when
comparing 4 weeks of tumour burden to PBS control mice
(Figure 1C).
Extrinsic regulators of skeletal muscle mass are
impaired throughout the development of cachexia
To determine the impacts of the tumour-bearing state on an-
abolic functions in the muscle, we assessed aspects of
myogenesis and protein synthesis. Briefly, myogenesis is the
formation of muscular tissue, which is necessary for repair
of injured muscle. Satellite cells are labelled with Pax7.43
Figure 1 Cross-sectional area throughout the progression of cancer cachexia. (A) Haematoxylin and eosin staining sample images (scale 50 μM). (B)
Mean CSA of TA muscle fibres throughout the progression of cancer cachexia. (C) Histogram of fibre sizes throughout the progression of cancer ca-
chexia. N of 7–8 was utilized for each group. Lettering denotes statistical significance (means that do not share the same letter are statistically differ-
ent) at an alpha set at P < 0.05.
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Upon activation, satellite cells express MyoD and subse-
quently Myogenin, which are responsible for proliferation
and differentiation of satellite cells, respectively.21,22 There
is evidence that myogenic dysregulation may promote
cancer-induced muscle wasting.20 From these assessments,
we observed that Pax7 mRNA content was ~35% lower
1 week following tumour implantation when compared with
PBS control mice and did not recover throughout the progres-
sion of cancer cachexia (Figure 2A).MyoD mRNA content was
~50% lower in both 1 and 2 week tumour-bearing groups
when compared with PBS control mice (Figure 2A). mRNA
content of MyoD recovered 3 weeks following tumour im-
plantation. In tumour-bearing mice, CyclinD1 mRNA content
was ~45% lower than PBS control mice in all tumour-bearing
groups (Figure 2A). Myogenin mRNA was ~50% lower than
PBS control mice 1 week following tumour implantation but
recovered by 3 and 4 weeks following tumour implantation
(Figure 2A). Finally, we assessed mRNA content of putative
markers of muscle denervation. We observed that while
mRNA of acetylcholine receptor (AchR) α, Gad45A, RUNX1,
and MusA were not significantly altered (Supporting Informa-
tion, Figure S1). AchR δ and AchR ε were down-regulated by
~35 and 45% 2 and 3 weeks following tumour implantation,
respectively (Supporting Information, Figure S1).
Mixed protein synthetic rate is lower in cachectic
muscle
Next, in our assessment of anabolic function, we deter-
mined 24 h FSR and assessed mTOR signalling components.
Mixed muscle FSR was ~40% lower than the PBS control
group 4 weeks following tumour implantation with no
other significant differences among experimental conditions
(Figure 3A). In contrast, there was no significant change in
myofibillar FSR during the progression of cancer cachexia
(Figure 3B); however, there was a mean decrease in the 3
and 4 week groups when compared with PBS (P = 0.3). To
examine mTOR-related signalling, we assessed the upstream
marker Akt, mTOR complex component and negative regula-
tor of mTOR–Deptor, and downstream mTOR targets
p70S6K1 and 4EBP-1.17,18,44 We observed that content and
phosphorylation of Akt, p70s6k, and 4EBP1 did not change
throughout the progression of cancer cachexia (Figure 3C).
However, Deptor protein content was ~40% greater 3 weeks
following tumour implantation when compared with other
experimental groups (Figure 3C).
Protein breakdown is up-regulated in cachectic
muscle
To investigate the contributions of putative catabolic pro-
cesses, we assessed markers of the ubiquitin-proteasome
system, autophagy, and apoptosis. With regard to the
ubiquitin-proteasome system, FOXO1 and FOXO3 signalling
are important regulators of the atrogenes: Atrogin1 and
MuRF1.23 These are important E3 ligases known to promote
skeletal muscle wasting.23 Muscle protein ubiquitination was
~50% higher than PBS control mice 4 weeks following tumour
implantation (Figure 4A). We observed that total FOXO1 pro-
tein content was ~50% greater than PBS control mice 4 weeks
following tumour implantation (Figure 4A). Phosphorylation
status of FOXO3T32 and FOXO4T28 did not change as tumour
growth progressed; however, therewas a non-significantmean
decrease in relative FOXO1T24 phosphorylation (Figure 4A).
Furthermore, Atrogin1 mRNA content was threefold greater
than PBS control mice 4 weeks after tumour implantation
(Figure 4B), whileMuRF1mRNA content was twofold and four-
fold greater than PBS control mice at 3 and 4 weeks following
tumour implantation (Figure 4B), respectively.
To provide insight into the potential contributions of
autophagy, a process involved in the formation of an
autophagosome in order to facilitate lysosomal clearance of
proteins and organelles,26–28 we examined upstream regula-
tor Beclin1, as well as LC3 (involved in the closing of the
autophagosome) and p62 (a linker protein between the
autophagosome and cargo that is degraded by the lysosome
upon completion of autophagy). Beclin1 protein content was
~80% greater than PBS control mice 4 weeks post-tumour
implantation (Figure 4C). Furthermore, total LC3 protein
content was ~60% higher than PBS control mice after 4 weeks
of tumour growth (Figure 4C). By contrast, there was no
difference in the LC3 II:I ratio throughout the progression of
cancer cachexia (Figure 4C) nor in protein content of p62
(Figure 4C).
Figure 2 Satellite cell and myogenic markers are impaired throughout
the development of cachexia. (A) Pax7 mRNA content throughout the
progression of cancer cachexia.MyoDmRNA content throughout the pro-
gression of cancer cachexia. CyclinD1 content throughout the progression
of cancer cachexia. MyoG content throughout the progression of cancer
cachexia. N of 7–8 was utilized for each group. Lettering denotes statisti-
cal significance (means that do not share the same letter are statistically
different) at an alpha set at P < 0.05.
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Apoptosis is not altered in progression of Lewis
lung carcinoma-induced cancer cachexia
To examine apoptosis in cachectic muscle, we used TUNEL
staining and Caspase 3 protein content. Loss of myonuclei
may limit the muscles’ ability to increase in size. There was
no significant difference in the number of TUNEL positive
nuclei throughout the progression of cancer cachexia
(Figure 5A). Moreover, total Caspase 3 was not different
between the PBS, 1, 2, 3, and 4 week groups (Figure 5B) while
Cleaved Caspase 3 (active form) was not detectable by
immunoblot.
MAPK phosphorylation is induced in
tumour-bearing mice
MAPKs are key controllers of both anabolic and catabolic
signalling within skeletal muscle45,46; therefore, in order to
assess MAPKs in cachectic muscle, we examined p38 and
ERK phosphorylation status. ERKT202/Y204 and p38T180/Y182
MAPK phosphorylations relative to respective total protein
contents were fourfold and threefold greater than PBS
control mice 4 weeks following tumour implantation, respec-
tively (Figure 6A/B).
ERK 1/2 inhibition does not protect against Lewis
lung carcinoma conditioned media-mediated loss
of myotube diameter despite promoting protein
synthesis
Considering that induction of MAPK phosphorylation occurs
concurrent with the development of muscle wasting in the
current study and the induction of a negative protein bal-
ance, we elected to examine MAPKs role in the development
of cancer cachexia in vitro. To do so, we used LCM treatment
of C2C12 myotubes to mimic cancer cachexia and appropriate
selective MAPK inhibitors for each experiment. First, to test
whether ERK MAPK inhibition could protect against LCM-
induced myotube atrophy, myotubes were concurrently
treated with PD98059. In these experiments, diameter of
myotubes treated with LCM was ~35% lower than the diam-
eter of myotubes treated with control media and was not af-
fected by the addition of PD98059 (Figure 7A). LCM loss of
myotube diameter was similar to the loss of muscle mass
Figure 3 Protein synthesis throughout the progression of cancer cachexia. (A) Mixed FSR throughout the progression of cancer cachexia. (B)
Myofibrilar FSR throughout the progression of cancer cachexia. (C) AKT phosphorylation relative to total protein content. Deptor protein content
throughout the progression or cancer cachexia. 4EBP1 phosphorylation relative to total protein content. p70s6k phosphorylation relative to total pro-
tein content. (D) Sample images for immunoblot analysis. N of 7–8 was utilized for each group. Lettering denotes statistical significance (means that do
not share the same letter are statistically different) at an alpha set at P < 0.05.
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observed in vivo (40% loss in CSA in vivo, 35% loss in myotube
diameter in vitro). Phosphorylated ERK relative to total ERK
was ~50% lower in groups containing PD98059 when com-
pared with the Control Media + Vehicle group (Figure 7B).
Also, ERK phosphorylation in LCM + Vehicle was ~50% lower
than Control + Vehicle (Figure 7B). Puromycin incorporation
was threefold and twofold greater in Control + PD98059
and LCM + PD98059, respectively, when compared with
Control + Vehicle (Figure 7C). Protein ubiquitination in LCM-
treated conditions were ~40% greater than control media
(Figure 7D). Protein content of p-4EBP1, 4EBP1, Deptor,
p-FOXO3, FOXO3, p-FOXO1, and FOXO1 was not different be-
tween all groups (Figure 7E). Atrogin-1 and MuRF-1 mRNA
content was ~25 and 35% lower in LCM + Vehicle when
compared with Control + Vehicle, respectively (Figure 7F).
Inhibition of p38 MAPK partially protects against
Lewis lung carcinoma conditioned media-mediated
loss of myotube diameter
Myotube diameter of cells treated with LCM + Vehicle was
~45% smaller than cells treated with control media, while
myotube diameter of cells treated with LCM + SB202190 was
~25% smaller than myotubes treated with control media and
~20% greater when compared with myotube diameter of cells
treated with LCM + Vehicle (Figure 8A). LCM loss of myotube
diameter was similar to the loss of muscle CSA observed
in vivo. Relative phosphorylation of MAPKAPK-2, a direct tar-
get of p38 MAPK, was ~40 and 50% in Control + SB202190
and LCM + SB202190 when compared with control vehicle, re-
spectively (Figure 8B). Puromycin incorporation was ~twofold
Figure 4 Protein breakdown throughout the progression of cancer cachexia. (A) Protein ubiquitination throughout the progression of cancer cachexia.
FOXO1 protein content throughout the progression of cancer cachexia. Phosphorylation of FOXO1 relative to total protein content throughout the pro-
gression of cancer cachexia. (B) Atrogin1mRNA content throughout the progression of cancer cachexia. (B)MuRF1mRNA content throughout the pro-
gression of cancer cachexia. (C) Beclin1 protein content throughout the progression of cancer cachexia. (C) Total LC3 protein content throughout the
progression of cancer cachexia. (C) LC3 II/I ratio throughout the progression of cancer cachexia. (C) p62 protein content throughout the progression of
cancer cachexia. (D) Representative immunoblot images. N of 7–8 was utilized for each group. Lettering denotes statistical significance (means that do
not share the same letter are statistically different) at an alpha set at P < 0.05.
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greater in myotubes treated with SB202190 when compared
with myotubes treated with vehicle, regardless of LCM treat-
ment (Figure 8C). Protein ubiquitination was ~twofold greater
in LCM + Vehicle when compared with all other groups
(Figure 8D). Protein content of p-4EBP1, 4EBP1, Deptor,
p-FOXO3, and FOXO3 was not different between all groups;
however, protein content of p-FOXO1 relative to total FOXO1
was significantly elevated in LCM + Vehicle when compared
with all other groups (Figure 8E). Atrogin-1 mRNA was ~45%
greater than control media groups using LCM + Vehicle treat-
ment and ~60% lower than control media groups using
LCM + SB202190 treatment (Figure 8F). MuRF-1 mRNA was
~70% lower in groups containing SB202190 when compared
with vehicle treatment (Figure 8F).
Figure 5 Apoptosis throughout the progression of cancer cachexia. (A) Percent TUNEL + Nuclei throughout the progression of cancer cachexia. (B) To-
tal caspase 3 protein content throughout the progression of cancer cachexia. (C) Sample images for the TUNEL assay including a positive control image.
(D) Representative immunoblot images. N of 7–8 per group was utilized. Lettering denotes statistical significance (means that do not share the same
letter are statistically different) at an alpha set at P < 0.05.
Figure 6 MAPK signalling throughout the progression of cancer cachexia. (A) ERK MAPK phosphorylation relative to total protein content. (B) p38
MAPK phosphorylation relative to total protein content. (C) Representative immunoblot images. N of 7–8 per group was utilized. Lettering denotes
statistical significance (means that do not share the same letter are statistically different) at an alpha set at P < 0.05.
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Discussion
Loss of muscle mass occurs largely from an imbalance of
protein turnover favouring protein degradation,47 which is
commonly observed in late stage cancer cachexia10,11,48;
however, we are the first to measure modalities of protein
turnover throughout a time course of the initial develop-
ment of LLC-induced cancer cachexia. In this same cohort
of animals, we recently demonstrated that impaired mito-
chondrial health develops well prior to onset of muscle
wasting.7 Those data thus suggest impaired myocellular
health prior to measurable muscle wasting. Here, we have
shown alterations in cellular programing necessary for the
maintenance of muscle mass as soon as 1 week following
tumour implantation with impaired signalling for satellite
cell proliferation and myogenesis. Interestingly, through ad-
ditional assessments of muscle protein synthesis and degra-
dative pathways including autophagy, ubiquitin-proteasome
system, and apoptosis, it appears primary decrements
contributing to the negative protein balance occur via acti-
vation of the ubiquitin-proteasome system and reduced
mixed muscle protein synthesis that develop concurrent
to the onset of phenotypic muscle wasting (by muscle
mass). Furthermore, upstream signalling suggests this may
Figure 7 Inhibition of ERK–MAPK does not protect against LCM mediated loss of myotube diameter despite promoting protein synthesis. (A) Myotube
diameter analysis of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059. (B) ERK MAPK phosphorylation relative to
total protein content following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. (C) Puro-
mycin incorporation for groups Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 after 30 min puromycin treat-
ment following 18 h of treatments. (D) Protein ubiquitination following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and
LCM + PD98059 treatment. (E) Protein content of p-4EBP1 relative to total 4EBP1, Deptor, p-FOXO3 relative to total FOXO3, and p-FOXO1 content rel-
ative to total FOXO1 following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. (F) Atrogin-1
and MuRF-1 mRNA content following 18 h of Control Media + Vehicle, Control Media + PD98059, LCM + Vehicle, and LCM + PD98059 treatment. All
measured in C2C12 myotubes and normalized to and Ponceau S. Data are mean ± SEM. (G) Representative micrograph and immunoblot images for
each protein of interest taken in order from same membrane. N of 6 was utilized for each group. Lettering denotes statistical significance (means that
do not share the same letter are statistically different) at an alpha set at P < 0.05. ME indicates statistical Main Effect of indicated factor(s).
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be mediated via activation of MAPK signalling cascades. In
fact, in vitro inhibition of p38 MAPK blunted myotube atro-
phy in response to LCM. The search for efficacious treat-
ments for cancer-induced muscle wasting is ongoing as
many attempted therapeutic modalities have yielded mini-
mal effect.49 The data presented in this study provide a
comprehensive overview of machinery responsible for the
maintenance of muscle mass throughout the development
of cancer cachexia in tumour-bearing mice.
Cross-sectional area is altered in tumour-bearing
mice
In the current study, cachectic muscle mass loss developed at
4 weeks post tumour implantation,7 which is commonly ob-
served in this model.7,16,39,50 At 4 weeks, these mice display
a degree of muscle mass loss (~15% smaller muscle wet
weights7 and a ~40% decrease in mean CSA) that would be
considered a negative prognosis clinically and greatly
Figure 8 Inhibition of p38 MAPK partially protects against LCM-mediated loss of myotube diameter. (A) Myotube diameter analysis of Control Me-
dia + Vehicle, Control Media + SB202190, LCM + Vehicle, and LCM + SB202190. (B) MAPKAPK-2 phosphorylation relative to total protein content fol-
lowing 18 h of treatments. (C) Puromycin incorporated for groups Control Media + Vehicle, Control Media + SB202190, LCM + Vehicle, and
LCM + SB202190 after 30 min puromycin treatment following 18 h of treatments. (D) Protein content of ubiquitin following 18 h of Control Media + Ve-
hicle, Control Media + SB202190, LCM + Vehicle, or LCM + SB202190 treatment. (E) Protein content of p-4EBP1 relative to total 4EBP1, Deptor, p-
FOXO3 relative to total FOXO3, and p-FOXO1 content relative to total FOXO1 following 18 h of Control Media + Vehicle, Control Media + SB202190,
LCM + Vehicle, or LCM + SB202190 treatment. (F) Atrogin-1 and MuRF-1 mRNA content following 18 h of Control Media + Vehicle, Control Me-
dia + SB202190, LCM + Vehicle, or LCM + SB202190 treatment. All measured in C2C12 myotubes and normalized to and Ponceau S. Data are
mean ± SEM. (G) Representative micrographs and immunoblot images for each protein of interest taken in order from same membrane. N of 6
was utilized for each group. Lettering denotes statistical significance (means that do not share the same letter are statistically different) at an alpha
set at P < 0.05. ME indicates statistical Main Effect of indicated factor(s).
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increase mortality among cancer patients. We do note that
CSA was reduced ~15% at 3 weeks post-tumour implantation
despite a lack of measurable change in total muscle mass.
However, the reductions in total muscle mass are smaller
than many prior reports and without significant loss in tu-
mour free body mass suggesting that 4 week tumour-bearing
mice displayed mild/moderate cachexia.
Extrinsic regulation of skeletal muscle mass
In cancer cachexia, the sarcolemma becomes damaged due
to factors secreted by the tumour, which elicits a repair re-
sponse.19 Our data indicate Pax7 mRNA, a satellite cell
marker, content decreased as soon as 1 week following
tumour implantation, implying the satellite cell pool may be
diminished thus impairing regenerative capacity shortly after
the onset of the tumour-bearing state.51 Intriguingly, these
results appear to contradict findings from He et al.20 in which
an increase in Pax7 protein content was noted in response to
tumour burden in both C26 and LLC models of cancer
cachexia. These contradictions may be due to methodology
differences to measure Pax7 expression. It is possible that re-
duced Pax7 mRNA here coupled with increased Pax7 protein
previously reported20 indicates altered turnover of Pax7 and
accumulation of dysfunctional satellite cells, at current
though this speculation requires further testing to resolve.
Moreover, our data show that MyoD (important for satellite
cell proliferation22), MyoG (important for satellite cell differ-
entiation22), and Cyclin D1 mRNA contents are decreased
1 week following tumour implantation. This dysregulation
of MyoD and MyoG mRNA expression corroborates recent
findings outlining impaired myogenesis in response to tu-
mour burden in mice.20 These data strongly suggest a defect
in myogenic regulation that develops shortly following onset
of the tumour-bearing condition and thus an early develop-
ment in this anabolic process. Interestingly, in our prior mea-
sures of mitochondrial degeneration the primary defect
therein at this early timepoint was an enhanced mitochon-
drial ROS emission.7 These combined data suggest in the
early tumour-bearing state initial defects in myogenic regula-
tion and mitochondrial ROS emission, although at this time it
is too early to state if these alterations are impacting one an-
other. The currently assessed aberrant myogenic signalling
suggests a potential limit on muscle regrowth potential that
develops shortly after onset of the tumour-bearing state.
Prior findings have suggested that satellite cell proliferation
is not necessary for muscle regrowth52,53; however, most of
these findings are in conditions where myonuclei may not
be compromised. We have seen here that in this earlier state
of cancer cachexia, apoptosis is not heavily induced, this ob-
servation is likely tied to attempts to preserve myonuclei in
conditions where the satellite cell pool is compromised that
may then limit muscle regrowth potential following loss of
myonuclei. This effect may then limit efficacy of therapies
aimed to reverse cachexia post-cancer treatment, thereby
suggesting a need to determine mechanisms impairing
myogenic potential in early tumour-bearing states to
prevent/reverse this effect.
Interestingly, we observed a rebound in the contents of
the myogenic regulatory factors MyoD and myogenin at 3
and 4 weeks post-tumour implantation. We cannot be certain
as to the mechanism for this; however, these specific myo-
genic regulatory factors have previously been demonstrated
to be elevated during denervation.54–56 Therefore, we
assessed a panel of denervation markers. To that end, we
have demonstrated that AchR δ and ε are down-regulated
in cachectic muscle; however, at this point, we cannot con-
clude that functional denervation is occurring. In fact, AChR
density is often higher than needed for efficient capture of
the acetylcholine released at the neuromuscular junction57;
therefore, based on current data, functional denervation is
not likely occurring at this stage in the development of cancer
cachexia. Therefore, the mechanism for the rebound effect in
MyoD and myogenin remains elusive. However, we should
caution that further studies into more severe cachectic states
may be necessary to determine impacts on functional
denervation.
Mixed muscle protein synthesis is reduced
concurrent to onset of muscle wasting in
tumour-bearing mice
In cancer cachexia literature, there is an ongoing debate as to
whether a decrease in protein synthesis, up-regulated protein
degradation, or both play a greater role in the onset of
cancer-induced muscle wasting.58 There appear to be dis-
crepancies based on both the type of model used and the
methodology for measuring protein synthesis.16,48,58–60 Our
protein synthesis data showed a decrease in the mixed mus-
cle fraction with no significant change in the myofibrillar frac-
tion (despite a ~25% mean decrease in FSR) measured over a
24 h time period. These results corroborate studies such as
Toledo et al.59 that describes a ~50% reduction in mixed pro-
tein synthesis in the gastrocnemius muscle in LLC tumour-
bearing mice. We are the first to measure protein synthesis
in LLC tumour-bearing mice utilizing deuterium oxide for a
24 h time period, a validated measurement of protein synthe-
sis.32 Typically in cancer cachexia literature protein synthetic
rates have been examined in shorter time periods.16,48,58–61
Our approach may provide a specific advantage in the ability
to assess protein synthetic function over the course of a full
light/dark cycle and thus a potentially more accurate reflec-
tion of protein synthetic rates. In regard to myofibrillar pro-
tein synthesis, we should note that most reports measuring
muscle protein synthesis in a cachectic phenotype utilize con-
ditions with more severe wasting and concomitant greater
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losses in muscle and total body masses than this
study.15,16,59,62 It is likely that development of a more severe
phenotype would alter protein synthetic signalling and in-
duce a more severe loss of myofibrillar FSR comparable with
other studies. These data suggest that decrements in mixed-
muscle protein synthesis are a significant contributor to
muscle wasting in LLC tumour-bearing mice.
Induction of skeletal muscle protein degradation
systems in tumour-bearing mice
Our data indicate that there is increased protein breakdown
4 weeks after tumour implantation. We note up-regulation
of E3 ligases Atrogin1 and MuRF1 4 weeks following tumour
implantation with concomitantly significantly increased pro-
tein ubiquitination. This increase in the ubiquitin-proteasome
system likely occurs through enhanced FOXO1 content, which
is responsible for promoting the expression of atrogenes such
as Atrogin1 and MuRF1.63–65
Autophagy is another key controller of protein break-
down.26–28 Our data indicate an increase in Beclin1
and LC3 protein content 4 weeks following tumour-
implantation. Based on current data, it appears that basal
rates of autophagy are not significantly affected (lack of
change in LC3II:I ratio and p62 content) in the cachectic
state; however, autophagy machinery (Beclin1 and LC3)
appears to be up-regulated suggesting greater capacity for
protein degradation through this system in cachectic mus-
cle. Finally, as discussed earlier in relation to the regulation
of myonuclei, we observed no significant induction of apo-
ptosis in the muscle of cachectic mice, suggesting that at
this stage of mild/moderate cachectic wasting, apoptosis
is not a primary contributor to muscle catabolism. However,
we cannot, based on our data, rule out that apoptosis may
play a more prominent role in muscle losses as the degree
of cachexia becomes more severe. In that situation, the
concomitant impairments in myogenic regulation we have
observed may become more critical in muscle regrowth
and recovery.
Therefore, in our assessments of muscle anabolic and cat-
abolic functions in tumour-bearing mice, we observe early
onset decrements to myogenic signalling, followed by re-
duced mixed muscle protein synthesis, increased ubiquitin-
proteasome function, and an up-regulation of autophagy
machinery. Prior studies of protein turnover with progression
of cancer cachexia have largely focused on the worsening of
the cachectic state itself.15 In those works, it is apparent that
negative protein balance becomes further exacerbated with
the overall condition in greater decrements of protein syn-
thesis and inductions of catabolic systems. Combined with
present findings, we now see that negative protein balance
(reduced synthesis and enhanced breakdown) occurs con-
comitant with the onset of muscle loss regardless of body
mass losses. Loss of protein synthesis and the promotion of
protein breakdown occur concomitantly with the onset of
cancer-mediated muscle loss.
MAPK signalling is altered in tumour-bearing mice
To identify potential signalling mechanisms leading to im-
paired protein anabolism and enhanced protein breakdown,
we next examined MAPK signalling in tumour-bearing mice.
Our data show that both ERK and p38 MAPK phosphoryla-
tions increase by fourfold and threefold, respectively, con-
current with the negative protein balance observed in this
study. Prior literature shows that an increased phosphoryla-
tion, and corresponding activation, of these MAPKs can lead
to both impaired muscle regeneration and increased protein
breakdown.45,46,66–70 In order to examine MAPKs role in
promoting cancer cachexia, we subsequently elected to
use LLC-conditioned media, a well-established model to
mimic tumour-mediated muscle wasting in vitro.30,31 We ob-
served a partial rescue of tumour-mediated loss of myotube
diameter by inhibiting p38 MAPK, with no effect of ERK
MAPK on LCM-induced myotube atrophy. Long-term
(~18 h) p38 inhibition appeared to prevent tumour-derived
catabolism (protected against LCM-induced protein
ubiquitination and up-regulation of Atrogin1) and promoted
protein synthesis. Of note, long-term inhibition of both p38
and ERK MAPK stimulated protein synthesis in vitro regard-
less of LCM treatment. However, it is interesting to note
that while ERK MAPK inhibition promoted protein synthesis,
it did not protect against LCM-induced atrophy suggesting
that p38 MAPK’s inhibition of protein ubiquitination and
atrogenes (likely independent of FOXO regulation) was likely
a key to protect from LCM-induced atrophy. We do note as
a limitation in the current experiment that we were unable
to detect induction of p38 and ERK MAPK phophorylations
in vitro. We should note, however, that prior similar
experiments have observed induced p38 and ERK MAPK
phosphorylation following 72 h LCM treatment30 suggesting
that detection of these inductions may require a longer
time period of exposure, and thus, we expect here that
timing of our assessments may have prevented us from
being able to measure induced activation of these MAPKs.
The authors find it interesting to note that 72 h course of
exposure to LCM30 compared with the 24 h exposure here
may be necessary to detect induction of p38 and ERK phos-
phorylations with the LCM model is consistent with our
in vivo evidence in which these alterations are not apparent
until later in the development of LLC-induced muscle
atrophy. While at this point, we cannot determine whether
inhibition of MAPK protects adult skeletal muscle from
tumour-mediated wasting in vivo; these data provide a
promising potential mechanism for the onset of cachectic
muscle wasting via p38 MAPK phosphorylation. In fact,
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recent evidence suggests that p38 MAPK blockade, or dele-
tion of the p38β isoform in skeletal muscle, blocks Activin A
induced catabolic signalling and completely protects against
Activin A-induced myotube atrophy.68 Interestingly, efforts
to more directly test effects of proteasomal inhibition have
led to mixed results with some protection in muscle atrophy
by specific targeting of MuRF171 and no protection seen
with the proteasome inhibitor Bortezomib,72 while growth
hormone secretagogues attenuate both induction of MuRF1
and muscle wasting.73 These data suggest the effects of p38
MAPK inhibition are likely at least in part due to protection
against MuRF1-ubiquitin-proteasome induction. Overall,
protection against catabolic functions, as performed here
via p38 MAPK blockade, and in other studies through other
means may be a key to attenuation of cancer-induced mus-
cle wasting.71,74,75 Combined with prior findings it now ap-
pears that p38 MAPK signalling may be a key regulator of
cancer-induced muscle wasting. Additionally, more research
is needed to elucidate the underlying mechanisms responsi-
ble for the observed stimulation of protein synthesis via
long-term MAPK inhibition. Our current data both in vivo
and in vitro are suggestive of the importance of the cata-
bolic p38-FOX01-atrogene-ubiquitin proteasome axis in the
development of cancer-induced muscle wasting. New stud-
ies should aim to determine if inhibition of p38 MAPK
in vivo may alleviate cancer-induced muscle wasting.
Summary and conclusions
In this study, we have analysed muscle size, myogenesis,
protein turnover, and apoptosis throughout the progression
of cancer cachexia. Based on our data, loss of mixed protein
synthetic rates along with increased protein breakdown via
the ubiquitin-proteasome system are likely the major
contributors for the onset of cancer-induced muscle wasting
in LLC tumour-bearing mice that develop at the onset of
muscle wasting. Furthermore, there appear to be early alter-
ations in myogenic signalling potentially contributing to the
irreversibility of cancer cachexia. Aberrant p38 MAPK signal-
ling is a likely major contributing factor in the onset of LLC-
induced cancer cachexia as p38 MAPK phosphorylation is in-
duced concomitant to developments of negative protein bal-
ance and muscle loss in tumour-bearing mice and p38 MAPK
inhibition partially protected against LCM-induced myotube
atrophy in vitro. The search for efficacious therapeutic strat-
egies in cancer cachexia and other wasting disorders con-
tinues, while strategies to target various functional aspects
within the muscle have had some effect,76,77 it appears that
the inhibition of catabolic systems may be a key to preserva-
tion of mass. Therefore, future research should continue to
examine the potential of targeting p38 MAPK and the anti-
catabolic effects therein in cancer cachexia induced muscle
wasting. These data provide novel information for the
mechanisms contributing to muscle atrophy and potential
insight for development of therapies to prevent and treat
cancer cachexia.
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